source
- Amgen's daxdilimab shows 6-point CLASI-A reduction in phase 2 lupus trialAmgen reported data from its phase 2 study of the ILT7-targeting monoclonal antibody daxdilimab in patients with discoid lupus. The trial enrolled 72 patients and tested two dose levels. The lower…
- Beam Therapeutics files lawsuit accusing former scientist of stealing IP to launch Chinese biotech ventureBeam Therapeutics has initiated legal action alleging that a former employee misappropriated proprietary gene-editing technology. The company claims the scientist used the stolen information to co…